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                                              ABSTRACT 
BACKGROUND:  
 Type 1 Diabetes Mellitus is a chronic endocrine disorder of children and 
early adults of autoimmune origin. It is often complicated by other autoimmune 
disorders especially autoimmune thyroid disease characterized by the presence 
of thyroid antibodies to peroxidase and thyroglobulin. Using these 
autoantibodies, organ-specific autoimmunity may be detected before the 
development of autoimmune clinical disease. Thus the aim of the study is to 
find the prevalence of thyroid disorder and thyroid autoimmunity status in type 
1 diabetes mellitus. 
METHOD:  
 Data were collected from 100 type 1 Diabetic patients. They were tested 
for thyroid profile (TSH, total T3 and T4) and thyroid autoimmunity (thyroid 
peroxidase antibodies). 
RESULTS:  
 The prevalence of thyroid disorder and thyroid autoimmunity was found 
to be 14% and 18% respectively in T1DM. Out of 18 thyroid peroxidase 
positive patients, 14 were hypothyroid and 4 were euthyroid. Over the 14 
hypothyroid, only 3 were overt hypothyroid and the remaining 11 were 
subclinical hypothyroid. There was female preponderance for thyroid 
xiii 
 
autoimmunity in T1DM.  There is also significant association T1DM and 
development of thyroid autoimmunity. 
CONCLUSION:  
 There is higher incidence of thyroid disorder in type 1 diabetes mellitus 
which is usually subclinical.  Coexisting thyroid disorder in type 1 diabetes may 
have a poor outcome on glucose control. Thus there is a need for periodic 
screening of thyroid profile in type1 diabetes mellitus. 
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INTRODUCTION 
 Type 1 Diabetes mellitus is a chronic autoimmune disorder of children and early 
adulthood due to destruction of beta pancreatic cells resulting in absolute insulin deficiency 
leading to  both microvascular and macrovascular complications in due course of time. 
 As Type 1 diabetes mellitus is a common endocrine disorder associated with 
aberrant immune responses to specific β-cell autoantigens including autoantibodies to 
glutamic acid decarboxylase (GAD), to islet cell (ICA) and to insulin (IAA), these patients 
are also prone to other autoimmune disorders such as Graves‟ disease, Hashimoto's 
thyroiditis, Addison's disease, vitiligo, celiac sprue, autoimmune hepatitis, myasthenia 
gravis, and pernicious anemia
1
. Using these autoantibodies, organ-specific autoimmunity 
may be detected before the development of clinical disease. 
 The most common autoimmune disease associated with T1DM is autoimmune 
thyroid disorder, which is characterized by the presence of thyroid antibodies especially 
thyroid peroxidase and thyroglobulin
2
. 
 In type 1 DM, the prevalence of thyroid antibodies in children is 8 to 50% from 
various studies in different nations due to variation in age, sex, and ethnic origin of the 
people. 
 Most patients with thyroid autoimmunity are asymptomatic. Even if symptomatic, 
symptoms may be attributed to diabetes. So, the diagnosis of thyroid dysfunction in 
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diabetic patients based solely on clinical manifestations can be difficult
3
.As both conditions 
involve a dysfunction of the endocrine system, thyroid disorders can have a major impact 
on glucose control, and untreated thyroid disorders affect the management of diabetes in 
patients
4
.Subclinical hypothyroidism is associated with an increased risk of symptomatic 
hypoglycaemia in diabetic patients while hyperthyroidism worsens glycemic control. 
 Because of this high prevalence, lack of clinical features and the impact on 
morbidity, most investigators recommend screening children and adolescents with type 1 
diabetes for autoimmune thyroid disease. Early detection has the potential to prevent 
significant morbidity related to unrecognized disease
2
. 
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AIMS AND OBJECTIVES 
  
 To study the prevalence and pattern of thyroid disorders in 
               Type 1 Diabetic patient. 
 To find out thyroid autoimmune status among them. 
 To correlate thyroid autoimmunity with thyroid dysfunction. 
 To assess any age/gender/diabetes duration difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
                       REVIEW OF LITERATURE 
 
DIABETES MELLITUS 
BACKGROUND OF DIABETES MELLITUS 
 Diabetes Mellitus is a metabolic disorder of multiple aetiology, characterised by 
chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both.  The long-term effects of 
diabetes cause damage and dysfunction of almost all organs of body in the form of both 
microvascular and macrovascular complications. Microvascular complications include 
progressive development of retinopathy with potential blindness, nephropathy that may 
lead to renal failure, neuropathy with risk of foot ulcers, amputation, Charcot joints, and 
features of autonomic dysfunction, including sexual dysfunction. Macrovascular 
complications include myocardial infarction, cerebrovascular accident and peripheral 
vascular accident. 
HISTORY 
 The first mention of diabetes as a condition causing 'polyuria' was first made about 
1500 B.C. in Papyrus Ebers found at Luxor in Egypt. A report from China indicated that 
the urine of diabetic patients was so sweet that dogs were attracted to it and a little later, 
around 400 B.C., the sweetness was referred to as “honey urine” 
 The word diabetes was first used by Aretaeus of Cappadocia in the second century 
AD. It comes from the Greek word meaning Siphon. Clinical description of polyuric states 
resembling diabetes mellitus was described in Ebers papyrus of Egypt (15 century BC) 
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PREVALANCE 
 DM is an epidemic disease seen throughout the world, but is more observed in 
developed countries. The Asian and African countries will have the major disease burden 
by 2030.In 2011, according to Indian Council for Medical Research, there are 62.4 million 
diabetics and 77.2 million prediabetics in India. The diabetic prevalence is expected to 
increase from 171 million in 2000 to 366 million in 2030 globally with India sharing the 
major disease burden. The increase in incidence in developing countries is due to 
urbanization and lifestyle changes, perhaps most importantly the "Western-style" diet. 
Type 2 diabetes mellitus amongst Indians occurs at a younger age, the age at diagnosis 
being a decade earlier than in the west. Body mass is lower by 4 kg/m
2
 for males and 6 
kg/m
2 
for females. However abdominal obesity with increased weight to hip ratio is more 
common in Indian population 
CLASSIFICATION OF DIABETES 
 In 1979, a uniform terminology and a functional classification of diabetes was 
developed classifying diabetes into insulin dependent diabetes mellitus and non- insulin 
dependent diabetes mellitus by the National Diabetics Data Group in USA
5
. This was later 
modified by the WHO Expert Committees in 1980 and 1985.The present classification and 
diagnostic criteria were proposed by an International Expert Committee
6
, working under 
the sponsorship of the ADA in 1997 which was later accepted by WHO. 
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TABLE 1 ETIOLOGICAL CLASSIFICATION OF DIABETES MELLITUS
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DIABETES MELLITUS TYPE 1 
 Type 1 diabetes is one of the most common metabolic disorders which occurs due to 
an absolute insulin deficiency. The disease shows an acute onset, with severe symptoms 
including weight loss. Positive family history of diabetes is rare and ketonuria is common. 
The patients are dependent on exogenous insulin for metabolic control and survival. 
 T1 DM develops in people who are genetically predisposed. In addition, certain 
environmental triggers start the process of autoimmune destruction leading to complete β 
cell destruction and insulinopaenia that is characteristic of type 1 DM.  
 It is estimated that 50% to 90% of type 1 DM patients have evidence of auto-
antibodies and they are labeled as type 1A DM or autoimmune type 1 DM while the 
remaining are called type 1B DM or idiopathic type 1 DM. The prevalence of type 1B DM 
is reported to be 5% to 10% in Caucasian populations. 
 Markers of the immune destruction of the ß-cell include islet cell autoantibodies, 
autoantibody to insulin, autoantibody to glutamic acid decarboxylase GAD, and 
autoantibody to the tyrosine phosphatases IA-2 and IA-2ß. One and frequently more of 
these autoantibodies are present in 85– 90% of individuals when fasting hyperglycemia is 
initially detected. These antibodies can be measured in the majority of patients, and may 
help determine which individuals are at risk for developing T1DM. 
 In type 1 diabetes, the rate of ß-cell destruction is quite variable, being rapid in some 
individuals (mainly infants and children) and slow in others (mainly adults). Some patients, 
particularly children and adolescents, may present with ketoacidosis as the first 
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manifestation of the disease. Others have modest fasting hyperglycemia that can rapidly 
change to severe hyperglycemia and/or ketoacidosis in the presence of infection or other 
stress. These patients are also having a tendency to other autoimmune disorders such as 
Graves‟ disease, Hashimoto‟s thyroiditis, Addison‟s disease, celiac sprue, and pernicious 
anemia. 
 
  FIGURE 1: PATHOGENESIS OF TYPE 1 DIABETES MELLITUS 
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DIABETES MELLITUS TYPE II 
 This type of diabetes, which accounts for 90% of those with diabetes, previously 
referred to as non-insulin-dependent diabetes, or adult-onset diabetes which usually 
diagnosed in patients >45 years but can occur in children and early adulthood. Type 2 
diabetes is caused by the interaction of certain genetic abnormalities with adverse 
environmental factors.Type 2 diabetes is a polygenic disorder, caused by a cluster of 
susceptibility genes. These patients have relative insulin deficiency due to insulin 
resistance. 
 Most patients with this form of diabetes are obese, and obesity itself causes some 
degree of insulin resistance. Patients who are not obese by traditional weight criteria may 
have an increased percentage of body fat distributed predominantly in the abdominal 
region. Unlike type 1 diabetes ketoacidosis seldom occurs spontaneously in this type of 
diabetes. It usually arises in association with the stress of another illness such as infection. 
This form of diabetes frequently goes undiagnosed for many years because the 
hyperglycemia develops gradually and at earlier stages is often not severe enough for the 
patient to notice any of the classic symptoms of diabetes. Nevertheless such patients are at 
increased risk of developing macrovascular and microvascular complications. Insulin 
secretion is defective in these patients and insufficient to compensate for insulin resistance. 
Insulin resistance may improve with weight reduction and/or pharmacological treatment of 
hyperglycemia but is seldom restored to normal. The risk of developing this form of 
diabetes increases with age, obesity, and lack of physical activity. It occurs more frequently 
10 
 
in women with prior GDM and in individuals with hypertension or dyslipidemia and its 
frequency varies in different racial/ethnic subgroups. 
GESTATIONAL DIABETES MELLITUS 
 Glucose intolerance that develops during pregnancy and typically resolves with 
delivery, occurs in about 7% of all pregnancies. This occurs because of insulin resistance 
due to pregnancy, overweight, obesity and genetic predisposition. It is a strong risk factor 
for later development of type 2 Diabetes 
DIABETES MELLITUS SYMPTOMS 
 The symptoms of uncontrolled diabetes are related to high blood glucose levels, and 
loss of sugar in urine. Elevated glucose in urine causes increased urination leading to 
dehydration which in turn increases thirst and water consumption. The inability to utilize 
glucose energy eventually leads to weight loss despite an increase in appetite. Type 1 
Diabetics have abrupt onset of signs and symptoms of hyperglycemia: increased thrist and 
hunger, frequent urination, weight loss, and fatigue and are more prone to develop 
ketoacidosis. Type 2 Diabetics are not prone to ketoacidosis until late in course or with 
prolonged hyperglycemia. They may also have blurred vision, delayed healing, numbness 
and tingling of the hands and feet, recurring fungal infection.  Elevated glucose levels can 
also lead to lethargy and diabetic coma. 
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DIABETES MELLITUS DIAGNOSIS 
 The American Diabetes Association (ADA) criteria for the diagnosis of diabetes are 
any of the following for non-pregnant adults of Type 1 and Type II 
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AUTOANTIBODIES AS MARKERS OF DM 
 T1DM is an autoimmune disease, as pancreatic ß cells are destroyed. The strongest 
evidence to support autoimmunity as the ultimate pathogenesis comes from the presence of 
insulitis (presence of inflammatory cells consisting of T lymphocytes, B lymphocytes, and 
macrophages) around the islets in recently diagnosed patients of type 1 DM. Fifty per cent 
to ninety per cent of type 1 DM patients have presence of antibodies against, islet cells 
(ICA), Glutamic Acid Decarboxylase (GAD), and IA2. Moreover type 1 DM has a strong 
association with other autoimmune disorders, like Hashimoto‟s thyroiditis, Grave‟s 
disease, pernicious anaemia, coeliac disease, etc.  
 Subjects with genetic predisposition to type 1 DM, if exposed to certain 
environmental trigger, autoimmune destruction of β-cells starts. These antibodies can be 
detected in the subject long before development of type 1 DM as insulitis is slowly 
progressive disease. However, all subjects with ICA or GAD – Ab do not necessarily 
develop type 1 DM.  
 Insulin antibodies carry a very small risk of type 1 DM, but its presence along with 
ICA increases the 5-year risk of type 1 DM to 50% to 70% particularly in childhood type 1 
DM below 5 years of age. Presence of two or more antibodies suggests a greater risk of 
type 1 DM.   Approximately 80% of patients with type 1 DM express two or more 
autoantibodies. 
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FIGURE 2: STAGES IN DEVELOPMENT OF TYPE 1 DIABETES 
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THYROID GLAND 
ANATOMY 
 The thyroid is one of the largest of endocrine organs, weighing about 15 to 20 gm in 
adults, with each lobe being approximately 4 cm (height) × 2 cm (width) × 2 to 2.5 cm 
(thickness). The two lobes are connected by the isthmus. The gland is formed of follicles, 
which are filled with colloid. From the apex of follicular cells, numerous microvilli extend 
into colloid. It is at or near this surface of the cell that iodination, exocytosis and the initial 
phase of hormone secretion occur. Colloid contains Thyroglobulin molecules in which 
thyroid hormones are present. 
REGULATION OF THYROID 
 The production of T4 and T3 in the thyroid gland is regulated by the hypothalamus 
and pituitary gland (figure 3). To ensure stable levels of thyroid hormones, the 
hypothalamus monitors circulating thyroid hormone levels and responds to low levels by 
releasing thyrotropin releasing hormone (TRH). This TRH then stimulates the pituitary to 
release thyroid stimulating hormone. When thyroid hormone levels increase, production of 
TSH decreases, which in turn slows the release of new hormone from the thyroid gland.  
 The thyroid gland needs iodine and the amino acid L-tyrosine to make T4 and T3. 
T3 is the biologically active form of thyroid hormone. The majority of T3 is produced in 
the peripheral tissues by conversion of T4 to T3 by a selenium-dependent enzyme. 
 Ninety-nine percent of circulating thyroid hormones are bound to carrier proteins, 
rendering them metabolically inactive. The remaining "free" thyroid hormone, the majority 
of which is T3, binds to and activates thyroid hormone receptors, exerting biological 
15 
 
activity. Very small changes in the amount of carrier proteins will affect the percentage of 
unboundhormones. 
 
 
 
 
 
 
FIGURE 3: REGULATION OF THYROID HORMONE 
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FIGURE 4: CLINICAL MANIFESTATION  OF THYROID DISORDER 
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THYROID AUTOIMMUNITY 
AUTOANTIBODIES AS MARKERS OF THYROID AUTOIMMUNE DISEASES 
 Thyroid autoantibodies is useful in disease prediction as it reflects the underlying 
disease activity and progression. Thyroid peroxidase and thyroglobulin are the most 
important autoantibodies associated with thyroiditis. Autoimmune thyroid disease (AITD) 
is the most common organ specific autoimmune disorder associated with both 
hypothyrodism and hyperthyroidism.  
 Autoimmune thyroid disease causes cellular damage through cell mediated 
destruction by sensitized T-lymphocytes and/ or autoantibodies binding to thyroid cell 
membranes leading to cell lysis and inflammatory reactions. Functional alterations in 
thyroid gland occur due to the action of stimulating or blocking autoantibodies on cell 
membrane receptors. The principal thyroid autoantigens are thyroid peroxidase (TPO), 
thyroglobulin (TG) and the TSH receptor. 
 Thyroid peroxidase (TPO) was initially known as „thyroid microsomal antigen‟ and 
thyroid peroxidase antibodies are the hallmark of autoimmune thyroid disease as they are 
associated with all cases of Hashimoto's thyroiditis, 60% of patients with postpartum 
thyroiditis and 75% of patients with Graves' hyperthyroidism. 
 Three principal thyroid autoantigens namely TPO, TG and the TSH receptor are 
involved in AITD.  It was found that the high TAA titres are consistently associated with 
AITD. 
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 It was found that that the autoantibodies to TG and TPO are characteristic serum 
markers of thyroid autoimmunity in humans and Abs to both autoantigens are mostly 
present in the same subjects. Thus, TG and TPO may share common Abs epitopes which 
suggest the presence of bispecific TgPO Abs in thyroid autoimmunity. TgPO Abs are 
reported to be detectable in most patients with high titres of TG Abs and TPO Abs but 
absent in patients without TG Abs 
 
FIGURE 5: PATHOGENESIS OF THYROID AUTOIMMUNITY 
DISORDERS 
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ASSOCIATION BETWEEN IMMUNE MEDIATED (TYPE 1) DIABETES 
MELLITUS AND AUTOIMMUNE THYROID DISEASES 
 Type 1 diabetes mellitus is a chronic illness of children caused by insulin deficiency 
due to destruction of the insulin – producing pancreatic beta cells.  The Onset commonly 
occurs in childhood but one - fourth of cases present in adults. Type 1 diabetic Patients 
with autoimmune mediated destruction of pancreatic beta cells are referred as type1 A 
which is  approximating 85 percent7.Patients who are clinically T1DM but without 
autoantibodies are referred as having T1 B diabetes which is approximately 15 percent.
 
 As T1DM is characterized by selective pancreatic β-cell destruction, the 
histopathology of T1DM is defined by a decreased β-cell mass with infiltration of 
mononuclear cells into the islets of Langerhans, which was described in 1901 by Opie
8
. 
This was known as „insulitis‟, and is the characteristic of type 1 diabetes mellitus. In 1965, 
insulitis was seen in 70% of acute onset T1DM and found to be caused by a beta cell 
specific autoimmune process as reported by Gepts
9
. In 1970s, Nerup demonstrated cellular 
autoimmunity in type 1 diabetics utilizing lymphocytic infiltration in islets
10
, therefore 
suggesting that an important role in the pathogenesis of T1DM was played by cell-
mediated immunity. Because type 1A diabetes is an immune-mediated illness that develops 
in a genetically susceptible person, it is not surprising that most patients with type 1A 
diabetes have one or more additional autoimmune diseases. The most common associated 
disorders are thyroid autoimmunity (Graves‟ disease or Hashimoto‟s thyroiditis) and celiac 
disease
11
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 The increased incidence of thyroid autoimmunity in type 1 diabetes was first 
reported in 1963
12
.In the 1980s, Riley et al. reported that thyroid function tests of young 
diabetic patients revealed that about 1% had Grave's disease (autoimmune 
hyperthyroidism) and about 7% had Hashimoto's disease (autoimmune thyroiditis). Again, 
another 10% of patients tested positive for thyroid microsomal autoantibodies without 
concurrent evidence of clinical disease 
13
. This frequency of antithyroid autoantibodies is 
about five times that found in healthy children of a similar age 
14
.The exact prevalenceof 
AITD among Indian adolescents with type 1 diabetes is still unknown. 
 In general, T1DM associated endocrinopathies are more common in patients with 
expressing HLA-DR3
15
. These individuals are dormant for a longer period of time before 
developing diabetes, presumably due to slower pace or later onset of beta cell destruction 
and are also positivefor anti-islet cell antibodies, compared with patients expressing HLA-
DR4, who are younger at time of diagnosis, positive for anti-insulin antibodies, and are less 
likely associated with other autoimmune endocrinopathies. 
 Up to 20 percent of patients with type 1 diabetes have positive antithyroid antibodies 
(anti-thyroid peroxidase and/or anti-thyroglobulin), and 2 to 5 percent of patients with type 
1 diabetes develop autoimmune hypothyroidism
16-21
. The prevalence of autoimmune 
thyroiditis is higher in girls with diabetes compared with boys, and it increases with 
age
21,22
. 
 Children with beta cell autoantibodies (glutamic acid decarboxylase: antiGAD) 
appear to have a higher risk of developing anti-thyroid antibodies 
21-23
. The presence of 
21 
 
anti-thyroid antibodies at diagnosis of T1D predicts the development of future thyroid 
disease 
20
. Patients with anti-thyroid antibodies are 18 times more likely to develop thyroid 
disease than patients without anti-thyroid antibodies 
21
.Specific HLA subtypes (for 
example HLA-DQB1*0302) have also been associated with greater risk of developing 
autoimmune thyroid disease 
17,24
. One study reported thatDR3-DQ2/DRB1*04:01-DQ8 is a 
susceptibility genotype for T1DM with autoimmune thyroiditis, while DRB1*11:01-
DQA1*05:05-DQB1*03:01 and DRB1*15:01-DQA1*01:02-DQB1*06:02 genotypes are 
protective 
25
.
 
 Patients with circulating antibodies may be euthyroid, or they may be hypothyroid 
and require thyroid hormone replacement therapy
16,26
. Rarely, they may be hyperthyroid 
with a reported prevalence of 1 to 2 percent in patients with type 1 diabetes. 
 The peak incidence of thyroid autoimmunity in young people occurs during early to 
mid-puberty, while in adults the risk is highest in middle-aged women . In children at 
genetic risk of Type 1 diabetes, seroconversion to thyroid peroxidase antibodies peaks 
around the time of puberty, at which time the thyroid gland undergoes remodelling. This is 
later than seroconversion to islet autoimmunity, suggesting that thyroid autoimmunity has 
different environmental trigger(s). 
 Biochemical thyroid dysfunction may present at diagnosisof Type 1 diabetes or may 
be detected after several decades of diabetes. There may be a prolonged period of thyroid 
autoimmunity prior to the development of thyroid dysfunction, but it is unknown whether 
22 
 
progression to clinical disease is more rapid in Type 1 diabetes than in the general 
population.  
 Type 1diabetes may be seen in association with hypothyroidism in Down‟s 
syndrome and also in patients with congenital rubella. Insulin requiring diabetes in 
association with primary hypothyroidism is sometimes seen in cases of haemochromatosis. 
Autoimmune polyglandular syndrome type 2 (APS 2) which is more common in women 
and occurs in early to middle adulthood is characterized by autosomal dominant 
inheritance and presence of autoimmune Addision‟s disease, autoimmune thyroid disease 
and immune mediated diabetes.  
 
     TABLE 3: THYROID DISORDER ASSOCIATED WITH T1DM 
S.NO  
1 
HASHIMOTO THYROIDITIS 
 Euthyroid 
 Hypothyroid 
2 GRAVES DISEASE 
3 POSTPARTUM THYROIDITIS 
4 
POLYGLANDULAR AUTOIMMUNE SYNDROMES(PAS) 
 PAS 1 
 PAS 2 
5 
CO-OCCURENCE WITH COELIAC DISEASE, 
ADDISON‟S DISEASE 
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FIGURE 6: ASSOCIATION BETWEEN DURATION OF T1DM AND AITM 
     
TABLE 4: GENES ASSOCIATED WITH T1DM, CD AND AITD    
 
GENES 
ASSOCIATED 
DISEASE 
HLA 
 DR3-DQ2,DR4-DQ8 
 DR3,DR5 
 DR3-DQ2 
 DR3-DQ2,DR4-DQ8 
 
T1DM 
AITD 
CD 
AD 
MIC-A T1DM,CD,AD 
PTPN22 T1DM,AITD,AD 
CTLA-4 T1DM,AITD 
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FIGURE 7: SCREENING OF OTHER AUTOIMMUNE DISORDES IN T1DM 
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THYROID REGULATION OF GLUCOSE HOMEOSTASIS 
 Thyroid hormone has profound effect on the regulation of glucose metabolism which 
exerts its effect on the circulating levels of insulin and counter regulatory hormones, 
hepatic output and peripheral utilization of glucose
27
. 
 Thyroxine stimulates liver gluconeogenesis and also improves peripheral glucose 
utilization in skeletal muscle and adipose tissue. It acts through direct and indirect 
mechanisms. Direct effect is by liver gene transcription and indirect effect by activating 
sympathetic pathway. But the central target is 5' adenosine monophosphate-activated 
protein kinase
27,28
. Thyroid hormones also modulate the gene expression of uncoupling 
proteins in brown adipose tissue thus altering thermoregulation. 
 Thyroid hormone nuclear receptors and type 4 melanocortin receptor are both 
expressed in the hypothalamus by TRH neurons. In hyperthyroid, T3 has a repressive 
effect on expression of MC4R thus conserving energy as of MC4R reduces food intake and 
increases energy expenditure
28
. 
EFFECTS OF THYROID HORMONE AT HEPATIC TISSUE 
T3 mainly targets genes involved in gluconeogenesis and glycogen metabolism 
1) Pyruvate carboxylase, the gluconeogenic enzyme involved in the formation of 
oxaloacetate through carboxylation of pyruvate in the mitochondria 
26 
 
2) Phosphoenolpyruvate carboxykinase (PEPCK), the enzyme that catalyzes the rate-
controlling step of gluconeogenesis by decarboxylation and phosphorylation of 
oxaloacetate to produce phosphoenolpyruvate
27,28
. 
 Thyroid exerts antagonistic insulin effect through decrease in protein kinase B 
expression which inturn decreases glycogen synthesis inactivating glycogen synthase 
kinase 3. Thyroid hormones facilitates glycogenolytic and gluconeogenic effects of 
epinephrine and glucagon through stimulation of β2-adrenergic receptor mRNA and 
suppression of inhibitory G protein (Gi) RNA of the adenylate cyclase pathway 
EFFECTS OF THYROID HORMONES AT PERIPHERAL TISSUES 
 In skeletal muscle, the main site of insulin-mediated glucose disposal, glucose 
transporter GLUT4 is induced by thyroid hormone. 
EFFECT OF DIABETES ON THYROID FUNCTION 
 There is inter-dependence between insulin and thyroid hormones for normal cellular 
metabolism so that diabetes mellitus and thyroid diseases can mutually influence the other 
disease process. In euthyroid individuals with diabetes mellitus, the serum T3 levels, basal 
TSH levels and TSH response to thyrotropin releasing hormone (TRH) may all be strongly 
influenced by the glycemic status. Poorly controlled diabetes, both Type 1 and Type 2, 
may induce a “Low T3 state” characterized by low serum total and free T3 levels, increase 
in reverse T3 (rT3) but near normal serum T4 and TSH concentrations. Low serum T3 is 
due to reduced peripheral conversion of thyroxine (T4) to tri-iodothyronine (T3) via 5‟ 
monodeiodination reaction. Studies indicate that it may be the long term diabetic control 
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that determines the plasma T3 levels. Poorly controlled diabetes may also result in 
impaired TSH response to TRH or loss of normal nocturnal TSH peak. TSH responses and 
“low T3 state” may normalize with improvement in glycemic status but even with good 
diabetes control, the normal nocturnal TSH peak may not be restored in C-peptide negative 
patients i.e. those with totally absent pancreatic beta cell function. 
Diabetes mellitus influences the assessment of thyrotoxicosis by falsely decreasing the 
blood levels of thyroxine (T4) and triiodothyronine (T3) during severely uncontrolled 
hyperglycemia.  
METABOLIC EFFECTS OF THYROID DYSFUNCTION ON DIABETES 
 The presence of thyroid dysfunction may affect diabetes control. Hyperthyroidism is 
typically associated with worsening glycemic control and increased insulin requirements. 
There is underlying increased hepatic gluconeogenesis, rapid gastrointestinal glucose 
absorption, increased insulin degradation, and probably increased insulin resistance. 
Indeed, thyrotoxicosis may unmask latent diabetes. 
 In practice, there are several implications for patients with both diabetes and 
hyperthyroidism. First, in hyperthyroid patients, the diagnosis of glucose intolerance needs 
to be considered cautiously, since the hyperglycemia may improve with treatment of 
thyrotoxicosis. Second, underlying hyperthyroidism should be considered in diabetic 
patients with unexplained worsening hyperglycemia. Third, in diabetic patients with 
hyperthyroidism, physicians need to anticipate possible deterioration in glycemic control 
and adjust treatment accordingly. 
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 Restoration of euthyroidism will lower blood glucose level. Although wide-ranging 
changes in carbohydrate metabolism are seen in hypothyroidism, clinical manifestation of 
these abnormalities is seldom conspicuous. The synthesis and release of insulin is 
decreased but there is reduced rate of insulin degradation that may lower the exogenous 
insulin requirement. The rate of hepatic glucose output is decreased probably due to 
reduced gluconeogenesis.  
 The net effect is an increased risk of recurrent hypoglycemia in a diabetic individual.  
More importantly, hypothyroidism is accompanied by a variety of abnormalities in plasma 
lipid metabolism, including elevated triglyceride and low-density lipoprotein (LDL) 
cholesterol concentrations. Even subclinical hypothyroidism can exacerbate the coexisting 
dyslipidemia commonly found in diabetes and further increase the risk of cardiovascular 
diseases. 
TABLE 5: DIABETES MELLITUS – THYROID DISEASE INTERACTION 
CLINICAL CONDITION 
EFFECT ON 
GLYCEMIA 
EFFECT ON THYROID 
FUNCTION 
Diabetes Mellitus-In euthyroid  
Individuals 
 
  Serum   T3     rT3 
   TSH response to TRH 
impaired noctural TSH peak 
Hyperthyroidism-In euglycemic 
individuals 
Glucose intolerance-in 50% 
cases overt diabetes in 2-3% 
 
Hyperthyroidism- in diabetic 
individuals 
Deterioration of diabetic control  
Hypothyroidism-in diabetic 
individuals 
Predisposition to recurrent 
hypoglycemia. Exacerbation of 
symptoms. 
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CONCLUSIONS 
 There is inter-dependence between insulin and thyroid hormones for normal cellular 
metabolism so that diabetes mellitus and thyroid diseases can mutually influence the other 
disease process. Hyperthyroidism results in deterioration of diabetic control while 
hypothyroidism increases the susceptibility to hypoglycemia in diabetic patients thereby 
complicating the diabetic management in these individuals.  
 Nearly one third of all newly detected Type 1 diabetes mellitus patients have         
co-existent thyroid autoimmunity (TAA) and a high prevalence of thyroid dysfunction 
which is predominantly hypothyroidism (clinical or subclinical) whilst a few have 
hyperthyroidism. The high prevalence of thyroid dysfunction emphasizes the importance of 
routine screening for TAI in all newly detected Type 1 diabetes mellitus patients followed 
by annual TSH assay in case TAA is positive.  
 Thyrotropin, also known as thyroid stimulating hormone (TSH), is the most useful 
screening test. In general, TSH should be tested several weeks after the diagnosis of type 1 
diabetes, when metabolic control has been established. This is because at least 20 percent 
of patients will have transient abnormalities of thyroid function when type 1 diabetes is 
first diagnosed, which resolve as the diabetes is treated . However, thyroid laboratory 
studies should be performed more promptly (within a few days of resolution of initial 
diabetes symptoms) in newly diagnosed children with clinical suspicion of thyroid disease 
because of thyroid enlargement or symptoms of hypo- or hyperthyroidism.   
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 If the TSH level is abnormal, free T4 is measured. 
 If the TSH level is normal, patients should have a repeat measurement every one to 
two years. Additional thyroid function testing should be obtained whenever thyroid 
dysfunction is suspected or thyromegaly is detected. 
 Patients with elevated TSH levels should be treated with thyroid hormone 
replacement therapy. The American Diabetes Association (ADA) suggests that 
antibodies to thyroid peroxidase (TPO) and thyroglobulin should be measured at 
diagnosis. An alternative strategy is to measure these antibodies only if 
abnormalities of thyroid function are detected. 
 If Graves‟ disease is suspected, then the thyrotropin receptor antibody should be 
measured. 
 If the initial antibody screening is positive, the patient should be monitored closely 
by screening with TSH annually and if any symptoms of hyper- or hypothyroidism 
develop. Repeat antibody testing is not needed 
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STUDIES ON TYPE 1 DIABETES AND THYROID 
DYSFUNCTION 
 Fuji et al. (1981) investigated thyroid hormone abnormalities in serum in 
47 patients with diabetes mellitus and reported that no significant differences in 
T4 but significantly higher reverse T3 (rT3) and lower T3 levels were found 
between diabetics and healthy controls. Moreover, patients in diabetic 
ketoacidosis showed markedly high rT3 with low T3 levels. They found that 
with insulin treatment, these levels returned to normal in several days. 
 Gray et al. (1981) investigated the clinical features of diabetics with 
coexisting Graves' disease, or primary hypothyroidism and found that those 
with Graves‟ disease developed thyroid dysfunction and diabetes at an earlier 
age than patients with primary hypothyroidism. There was, however, no 
difference between the two groups in respect of sex ratio or proportion of 
subjects requiring insulin treatment. They found a strong correlation between 
age at diagnosis of diabetes and that of hyperthyroidism or hypothyroidism. 
 Bagchi (1982) found several alterations in thyroid function in diabetes 
mellitus.The most profound changes occur in patients with insulin-dependent 
diabetes. Plasma T4 is normal, plasma T3 is diminished, and the plasma level of 
rT3 is elevated in diabetic ketoacidosis or in patients with severely uncontrolled 
diabetes. They suggested that these changes arise from alterations in the 
monodeiodination pathways of T4 and both hypo- and hyperthyroidism occur 
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with increased frequency in diabetes. Also there is an increased prevalence of 
thyroid autoantibodies in insulin-dependent diabetes.  
 Cardoso et al. (1995) determined thyroid function and the prevalence of 
thyroid autoimmunity in IDDM Africans and the results were compared with 
those of a nondiabetic group and a group with non-insulin dependent diabetes 
mellitus (NIDDM). Thyroid hormone levels were significantly lower in IDDM 
patients than in the control population and the NIDDM population. Subclinical 
hypothyroidism was present in 21 % of the 28 IDDM patients, whereas one 
patient was hypothyroid and another hyperthyroid. Of the 60 NIDDM patients, 
5 (8.3%) had subclinical hypothyroidism. Forty-six percent of the IDDM 
patients had significant levels of serum thyroid autoantibodies (TAA). This was 
significantly higher than the 1.4% and 1.7%, respectively in the controls and 
NIDDMs. Presence of TAAB in the patients was strongly associated with 
thyroid dysfunction, female preponderance, and duration of diabetes mellitus. 
 Lorini et al. (1996) assessed TAA thyroid autoantibodies (MsA and TgA)     
cross- sectionally in 212 children and adolescents (93 girls and 119 boys) aged 
1.2-21 years with IDDM from 0-18 years, and longitudinally in 90/212 (43 girls 
and 47 boys) at diagnosis and during a 3-10 year follow-up. In the cross-
sectional study, they found that TAA were present in 22/93 girls (23.7%) and 
13/119 boys (10.9%). In the longitudinal study TAA were observed at diagnosis 
in 6 patients, and during the follow-up in 9 girls. In 11/15 TAA positive 
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patient‟s anti-nuclear antibodies were also present. Thyrotoxicosis also occurs 
with increased frequency in diabetic children than in the general population. 
 Chang et al. (1998) in their study among 243 type 1 diabetic patients 
found, 53 (21.8%) were positive for antiTPO. Among the type 1 diabetic 
patients with thyroid autoimmunity, anti-TPO tended to occur in those of older 
age or with long-standing disease. The frequency of anti-GAD was 45.6% (99 
of 217), without gender preponderance (males: females, 18.0% vs 27.6%).Thus 
they reported that the presence of anti-TPO in 21.8% of type 1 diabetic patients 
confirmed the strong association of AITD and type 1 diabetes mellitus without 
ethnic differences. 
 Maugendre et al. (2000) during their study showed that thyroid 
peroxidase (TPO) antibodies were present in 45 of the 258 diabetic patients 
(17%) whereas thyroglobulin (Tg) antibodies were found in 19 patients (7%), 
including 13 cases with TPO antibodies. They found that prevalence of TPO 
antibodies were not influenced by such factors as gender, duration of disease, 
age at screening and at diabetes diagnosis, positivity of familial history. 
Thyroglobulin (Tg) antibodies were found in 19 patients (7%), including 13 
cases with TPO antibodies. All patients without TPO antibody (n=213), 
including Tg-positive patients displayed TSH values in normal range. From the 
45 TPO-positive patients they studied, 11 shows thyroid dysfunction. During 
their 5-year follow-up, only 2/45 patients became anti-TPO negative whereas 
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thirteen of the 45 patients developed subclinical or clinical thyroid diseases (4 
Graves' disease and 9 thyroiditis with hypothyroidism). 
 Rattarasarn et al. (2000) in their study of 50 Thai type 1 diabetic patients 
found that thyroglobulin (Tg-Ab) and thyroperoxidase antibodies (TPO-Ab) 
were positive in nine (18%) and 15 (30%) patients respectively whereas eight 
patients (16%) were positive for both antibodies. None of 34 patients without 
thyroid antibodies had thyroid dysfunction. They followed up eight patients 
with positive thyroid antibodies but without clinical thyroid dysfunction and 21 
patients without thyroid antibodies for up to 3 years and found that two patients 
of the first group developed hypothyroidism, whereas none of the latter 
developed thyroid dysfunction. 
 Kordonouri et al. (2002) in their multi center survey of 118 paediatric 
diabetic center in Germany and Austria reported the results of 7097 type1 
diabetic patients and found that in 1,530 patients, thyroid antibody levels were 
elevated on at least one occasion, whereas 5,567 were antibody-negative during 
the observation period. Thyroid-stimulating hormone (TSH) levels were higher 
in patients with thyroid autoimmunity (3.34 pU/ml, range 0.0-615.0 pU/ml) than 
in control subjects (1.84.pU/ml, range 0.0-149.0 pU/ml) (P < 0.001). Even 
higher TSH levels were observed in patients with both anti-TPO and anti-TG 
(4.55 uU/ml, range 0.0-197.0 pU/ml).Thus they found that thyroid 
autoimmunity seems to be particularly common in girls with diabetes during the 
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second decade of life and may be associated with elevated TSH levels, 
indicating subclinical hypothyroidism. 
 Radaideh et al. (2003) investigated the prevalence of thyroid dysfunction 
and autoimmunity in 79 type 1 diabetic patients and compared with normal 
control. They found a significant difference in thyroid function variables 
between diabetics and controls. Among type 1 diabetic patients, 7 (9.2%) had 
thyroid autoantibodies, 5 with positive TPOAb only and 2 with positive TgAb, 
compared with 8 (6.3%) in the control group, 4 with positive TPOAb only and 4 
with positive TgAb. Umpierrezet al. (2003) in cross sectional studies have 
reported that risk of thyroid dysfunction in patients with type 1 diabetes is two 
to three fold higher than in general population. They analyzed the incidence of 
thyroid dysfunction over time in a cohort of 58 patients (26 men and 32 women) 
and prospectively followed them for 18 years and reported that 18 patients had 
hypothyroidism, and 1 patient experienced transient hyperthyroidism. They 
found that hypothyroidism was more common in female (41 %) than in male 
(19%) subjects and in patients with positive TPO antibodies. Patients who were 
TPO positive were 17.91 times as likely to develop hypothyroidism as patients 
who were TPO negative (95% CI 3.89-82.54). There were no differences in 
BMI, lipid profile, and HbAlc  between patients with and without thyroid 
dysfunction. 
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Shomon (2003) has confirmed the linkage between autoimmune thyroid disease 
and type 1 diabetes, suggesting that diabetic patients should receive regular 
screening for thyroid dysfunction. 
 Hawaet al. (2006) in their study evaluated disease-associated 
autoantibodies in both type 1 diabetes and thyrotoxicosis attending the Central 
Hospital of Yaounde in Cameroon. They collected samples from a total of 101 
subjects, 47 of whom clinically had established type 1 diabetes, 18 had 
thyrotoxicosis and 36 normal subjects and tested for diabetes-associated 
glutamic acid decarboxylase (GAD) and tyrosine phosphatase (IA2) 
autoantibodies, thyroiditis-associated thyroglobulin (Tg) and thyroid peroxidase 
(TPO) autoantibodies .They reported that out of 47 patients with type 1 
diabetes, 16 (34%) had GAD autoantibodies (Abs), 3 (6.4%) had IA2 Abs, and 
2 (4.3%) had TPO Abs. Out of 18 patients with thyrotoxicosis, 4 (22.2%) had 
GAD Abs, 5 (27.8%) showed IA2 Abs, while 8 patients (44.4%) were TPO Abs 
positive. No patients in either group had TgAbs. Among normal subjects, 2 
(5.6%) showed GAD Abs, and one of these was also IA2 Abs positive, but none 
had thyroid autoantibodies. 
 Volzke et al. (2007) studied the spectrum of thyroid disorders in 224 
adult type diabetic subjects and compared them with results obtained from a 
sample of 3481 general adult population. They concluded that type 1 diabetic 
subjects had a higher risk of known thyroid disease, a lower risk of goiter and 
nodules and a higher risk of anti-TPO-Ab >200 IU/mL compared to the 
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reference population. Furthermore, diabetic subjects had lower serum FT3 
levels than the non diabetic references.  
  Araujo et al. (2008) investigated the prevalence of thyroid 
autoantibodies in 214 children, adolescents, and young adult with type1 diabetes 
from north eastern Brazil as well as their significance for the development of 
thyroid disorder. They found that anti-TPO antibody test was positive in 54 out 
of the 214 patients studied, resulting in an overall prevalence of 25.2%,with 
females were predominance (72%) over males (28%). A total of 55.5% patients 
with positive anti-TPO antibodies had abnormal TSH levels. 
 Korner et al. (2008) investigated the prevalence of thyroid autoimmunity 
as well as the frequency of autoimmune thyroid disease in patients with type 1 
diabetes mellitus and compared the prevalence of autoimmune thyroid disease 
in patients with type 1 diabetes mellitus and in those with type 1 diabetes 
mellitus and coeliac disease. Their results concluded that frequency of 
autoantibody positivity was significantly higher in diabetic patients suffering 
from celiac disease (type 1 diabetes mellitus: 43 (16%), type 1 diabetes mellitus 
+ celiac disease: 16 (33.3%, p < 0.01). Hypothyroidism due to thyroiditis was 
also more prevalent in patients with type 1 diabetes mellitus and celiac disease. 
 Monajemzadeh et al. (2009) investigated the prevalence of thyroid 
dysfunction among children and adolescents with newly diagnosed type 1 
diabetes in Iran for which they had compared 75 newly diagnosed type1 
diabetic subjects with 105 healthy control children. They reported the 
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prevalence of thyroid dysfunction in diabetics was 14.6% (9.3% were 
subclinical hypothyroidism, 4% hypothyroidismand 1.3% subclinical 
hyperthyroidism) which were higher than normal controls. 
 Muralidhara Krishna et al. (2011) evaluates the levels of TSH, TmAb and 
lipid parameters in 36 type l diabetes cases and found that TSH was 
significantly elevated in cases and TmAb was identified in 7 of the 36 cases 
studied. Presence of TmAb and elevation in TSH were more pronounced in 
female cases. They also reported that serum total cholesterol as well as LDL- 
cholesterol levels were significantly elevated and serum HDL-cholesterol was 
significantly lowered in type 1 diabetics. 
 Joshap et al. (2011) assessed thyroid function at the diagnosis of type 1 
diabetes and reported that 21/110 (19.0%) patients had abnormal thyroid 
function at diagnosis of TIDM. They found that abnormalities of thyroid 
function occurred more commonly in children with diabetic ketoacidosis (DKA) 
than those who did not have DKA( 31.0% vs. 14.8%,). 
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MATERIALS AND METHODS 
Study design: 
 Cross sectional observational study to analyse the prevalence of thyroid 
disorders and thyroid autoimmunity among Type 1 Diabetes. 
Setting: 
 The study was carried at diabetic clinic of the Government Mohan 
Kumaramangalam Medical College Hospital, Salem 
Approval: 
 The study was approved by the ethical committee of Government Mohan 
Kumaramangalam Medical College Hospital, Salem 
Study population: 
 100 Patients were enrolled from the patient  population who attended 
the outpatient clinic of Diabetology, from August 2014 to July 2015. 
Inclusion criteria: 
 Established cases of Type 1 Diabete , diagnosed based on standard 
criteria.  
 Symptoms of diabetes and casual plasma glucose 200 mg/dl (11.1 mmol/l) 
or 
 Fasting plasma glucose  126 mg/dl (7.0 mmol/l) or 
 2-h plasma glucose  200 mg/dl (11.1 mmol/l) and 
 Patient on insulin from the time of diagnosis of diabetes 
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Exclusion criteria: 
 Patients less than 14 years 
 Pregnancy 
 Evidence of other autoimmune diseases like Addisons disease, vitiligo, 
autoimmune hepatitis, rheumatoid arthritis, SLE.  
 Multinodular goiter and  known thyroid disease on medication 
 Past history of thyroid surgery or radioiodine therapy. 
CONSENT: 
 Patients were informed about the details of the test performed and blood 
sample were collected with consent. 
SAMPLE COLLECTION: 
 Venous blood sample were collected after 8 hours fasting state. After 
serum separation, samples were sent for analysis. 
METHOD OF TESTING: 
 T3, T4, TSH – Radio ImmunoAssay. 
 Thyroid peroxidaseAntibodies - Enzyme Linked Immuno Sorbent Assay. 
NORMAL RANGES: 
 T3                -80 – 180  ng/dl 
 T4                 - 4.2 - 11 μg/dl 
 TSH               - 0.5 – 5 mIU/ ml 
 TPOA <40 IU/ml 
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RESULT INTERPRETATIONS: 
 Any T3 /T4 value above the upper limit of normal along with a lowTSH 
< 0.5 mIU/ml is considered as hyperthyroidism. 
 Any T3 /T4 value below the lower limit of normal along with an elevated 
TSH > 5mIU/ml is considered as hypothyroidism. 
 TSH > 5mIU/ml along with normal range T3, T4 is considered as 
subclinical hypothyroidism. 
 TSH < 0.5 mIU/ml along with normal range T3, T4 is considered as 
subclinical hyperthyroidism. 
 Thyroid autoimmunity is considered to exist if TPOA level is > 40 IU/ml 
and not to exist if it is lesser. 
STATISCAL ANALYSIS: 
 Statistical analysis was done using standard formulae SPSS (Statistical 
Package for Social Sciences) in windows Dos version. Base line data like age, 
gender, duration of diabetes were collected. Patients were categorized based on 
their thyroid status and thyroid autoimmune status. The significance of 
difference between means in two groups was calculated using student t test and 
the significance of difference in proportions using chi-square test. Fisher exact 
test was used when any one of the values was less than 5 in chi-square test. 2 x 
2 tables were constructed for each variable and chi square value for a degree of 
freedom calculated.Statistical significance at 5% levels was taken for p value < 
0.05 and at 1% levels p < 0.001. 
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DISCUSSION 
In this study, 100 type 1 diabetic patients were enrolled and tested for this study 
Total number of patients    : 100 
Number of male    :  54 
Number of female             :  46 
Age range                :  14 – 34 
Mean age              :  21.8   5.5 years 
Mean duration of diabetes   :  9  4.5 years 
Total Number of hypothyroid      :14 
 Male       :  4 
Female     :  10 
Number of overt hypothyroid  :3 
Number of subclinical hypothyroid  :11 
Total number of hyperthyroid patients : nil 
Number of TPOA positive  : 18 
Male                  :  4 
Female              : 14 
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Number of TPOA positive with hypothyroidism  :14 
                                  Male  : 4 
                                  Female : 10 
Number of TPOA positive with euthyroidism :4 
                                Male  : 1 
                                 Female  : 3 
Mean age of patients with AITD            :  13.1 4.4YRS years 
Mean duration of diabetes of patients with AITD :   25.5  6.2 years 
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TABLE 6: THYROID STATUS IN RELATION TO GENDER IN 
ACTUAL NUMBERS 
 
THYROID 
STATUS 
 
                        GENDER 
 
 
TOTAL 
 
MALE 
 
FEMALE 
EUTHYROID 50 36 86 
HYPOTHYROID 4 10 14 
HYPERTHYROID NIL NIL NIL 
 
 On comparing the female and male ratio by chi square test, the p value is 
0.077 which is > 0.05. So, the association between gender and hypothyroidism 
is not significant indicating that there is no significant gender difference among 
hypothyroid and euthyroid type 1 diabetics as per this study. 
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CHART 1: THYROID STATUS IN RELATION TO GENDER IN 
ACTUAL NUMBERS 
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CHART 2: SCATTER PLOT DIAGRAM OF T3 VALUE OF ALL 
PATIENTS 
 
 
CHART 3: SCATTER PLOT DIAGRAM OF T4 VALUE OF ALL 
PATIENTS 
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CHART 4: SCATTER PLOT DIAGRAM OF TSH VALUE OF ALL 
PATIENTS 
 
 
 
 
 Charts 2 shows the scatter plot of T3 values obtained from the study 
population 
 Charts 3 shows the scatter plot of T4 values obtained from the study 
population 
 Charts 4 shows the scatter plot of TSH values obtained from the study 
population 
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TABLE 7: AGE DISTRIBUTION OF TYPE 1 DIABETES MELLITUS 
 
AGE GROUP NUMBER OF 
PATIENTS 
10-15 14 
16-20 31 
21-25 28 
26-30 16 
31-35 11 
36-40 NIL 
 
 Out of 100 patients, majority (31 patients) are in the age group of 16 to 
20, followed by 21 to 25 age group (28 patients). None were below 10 years as 
they are not included in the study and late adulthood are also less.  
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CHART 5: AGE DISTRIBUTION OF TYPE 1 DIABETES MELLITUS 
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TABLE 8: AGE DISTRIBUTION OF ONSET OF TYPE 1 DIABETES 
AGE OF ONSET 
NUMBER OF 
PATIENTS 
0-5 6 
6-10 20 
11-15 51 
16-20 16 
21-25 7 
26-30 NIL 
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TABLE 9: DISTRIBUTION OF DURATION OF T1DM 
 
DURATION OF 
DIABETES 
NUMBER OF 
PATIENTS 
0-5 6 
6-10 20 
11-15 51 
16-20 16 
21-25 7 
 
 
 
CHART 7: DISTRIBUTION OF DURATION OF T1DM 
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TABLE 10: THYROID AUTOIMMUNE STATUS IN RELATION TO 
GENDER IN ACTUAL NUMBERS 
 
 
 
THYROID 
AUTOIMMUNITY 
 
GENDER 
 
 
 
TOTAL 
 
MALE 
 
FEMALE 
 
 
TPOA NEGATIVE 
 
 
50 
 
 
32 
 
 
82 
 
 
TPOA POSITIVE 
 
 
4 
 
 
14 
 
 
18 
 
 On comparing the female: male ratio by chi square test, the p value is 
0.006 which is > 0.05 . So, the association between gender and thyroid 
autoimmunity is very significant indicating that there is significant gender 
difference among those who are positive for TPOA and those who are negative 
for the same in type 1 diabetics as per this study.Thus female are more prone to 
have thyroid autoimmunity than males. 
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CHART 8: THYROID AUTOIMMUNE STATUS IN RELATION TO 
GENDER IN ACTUAL NUMBERS 
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TABLE 11: CORRELATION BETWEEN THYROID FUNCTION AND 
AUTOIMMUNITY 
 
CATEGORY 
 
HYPOTHYROID 
 
EUTHYROID 
 
TOTAL 
TPOA 
POSITIVE 
14 4 18 
TPOA 
NEGATIVE 
0 82 82 
TOTAL 14 86 100 
 
 77% of TPOA positive patients are hypothyroid whereas none of TPOA 
negative patients are hypothyroid. 100% of hypothyroid patients are TPOA 
positive whereas none of them are TPOA negative. On comparing these two 
values by chi square test, the p value is <0.001 which is very statistically 
significant. So, the association between thyroid autoimmunity and 
hypothyroidism is very significant indicating that hypothyroidism is more 
prevalent among TPOA positive individuals than in TPOA negative individuals. 
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CHART 9: THYROID STATUS OF TPOA POSITIVE PATIENTS 
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CHART 10: THYROID ANTIBODY STATUS IN STUDY POPULATION 
 
 
CHART 11: STATUS OF TPOA POSITIVE HYPOTHYROID PATIENTS 
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TABLE 12: THYROID AUTOIMMUNITY IN RELATION TO 
DURATION OF DIABETES 
 
 On comparing the two means by student t test, the p value is 0.0002 
which is < 0.05. So, the association between thyroid autoimmunity and duration 
of diabetes is very significant indicating that prevalence AITD is related to 
duration of diabetes as per this study 
 
 
 
 
 
 
 
AUTOIMMUNE STATUS 
 
 
MEAN DURATION OF DIABETES 
IN YEARS   SD 
 
TPOA POSITIVE 
 
13.17  4.5 
 
TPOA NEGATIVE 
 
8.23   4 
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TABLE 13: THYROID AUTOIMMUNITY IN RELATION TO AGE 
 
 
 
 
 
 
 
 
 
 
 On comparing the two means by student t test, the p value is 0.002. So, 
the association between prevalence of thyroid autoimmunity and age of 
diabetics is significant, indicating that prevalence of AITD is related to age of 
the patients as per this study 
 
 
 
 
 
 
 
 
THYROID            
AUTOIMMUNITY 
 
MEAN AGE IN YEARS 
 SD 
 
TPOA POSITIVE 
 
25.6  6.3 
 
TPOA NEGATIVE 
 
20.9  5 
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INTERPRETATION OF RESULTS 
 Most of the TPOA positive individuals have abnormal thyroid function. 
 Abnormal thyroid function is mainly in the form of subclinical.  
 Hyperthyroidism is seldom seen. 
 Hypothyroidism is more common among those who are positive for TPOA 
 
. 
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DISCUSSION 
 The study showed the high prevalence of a second organ-specific 
autoimmune manifestation in individuals with type 1 diabetes. By cross 
sectional analysis, the prevalence of thyroid autoimmunity in our study 
population is 18% (18 out of 100). This is in concordance with many other 
similar studies from various parts of the world. 
  Most of the studies state the prevalence to be between 15 to 30%.  
Roldán MB et al
30
-17.6%;  
Prázný M
31
- 22%,  
McCanlies E
32
-26.6% , 
Maugendre D et al
33
- 9-17%. 
 Initial screening of type 1 diabetic patients at the time of diagnosis, for 
the presence of thyroid antibodies was done by Gemma et al
34
 in march 2007 
and  O Kordonouriet al
35
 in 2005 and they found out TPOA positivity in 14.2% 
and 15.4% respectively. 
 Study by Aaron Hanukoglu et al
36 
is a multicenter cross sectional study 
which included both newly diagnosed as well as previously diagnosed 
patients.They give the prevalence as 27%. 
 Same study says the prevalence in first degree relatives as 25%. Similar 
single time measurement of antibodies was done by Jennifer M. Barker etal
37
 
which showed the prevalence as 29%.  
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 Many longitudinal studies have shown a still higher prevalence due to 
late appearance of thyroid peroxidase antibodies. Adriana Franzese et el
38 
diagnosed 50% of AITD patients at initial screening, remaining 50% on follow 
up. Longitudinal study by Guillermo E. Umpierrezet al
39
 has shown it to be 33% 
but most of tested positive in the beginning itself. 
 A study by Menon et al
40
, conducted in Department of Pediatrics, All 
India Institute of Medical Sciences, New Delhi in 2001, is the only Indian study 
available in this context. According to this study TPO prevalence is 54.3%. This 
is a higher value when compared to our study as well as many other studies. But 
the limitation of this study is that, only 35 patients were included. 
 Sarah J. Glastras et al
41
 and D Hansen et al
42
 give relatively lower values 
of 7.8% and 12.9% respectively. 
 While most of the studies included patients of any age, the one by Miguel 
Fernandez-castaneret al
43 
is similar to ours. They included only adult population 
of age > 14 years and found out the prevalence to be 27.9% 
 Thus, our study on type 1 diabetes supports previous studies in terms of 
AITD prevalence. 
PREVALENCE OF THYROID DYSFUNCTION IN TYPE1 DIABETES 
 The reported prevalence of thyroid dysfunction in diabetic population 
varies widely between studies. But, thyroid dysfunction is seen particularly in 
those who are positive for thyroid autoimmunity and so the presence of thyroid 
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autoimmunity is considered to predict the future development of thyroid 
dysfunction. 
 O Kordonouri et el
35
 performed a long term, large scale study, which 
included 659 T1D patients. The cumulative incidence of hypothyroidism at 10 
years of observation time was 0.69 (0.08) in positive anti- TPO compared with 
0.12 (0.05) in 539 patients with negative anti-TPO measurements (p < 0.001) 
Guillermo E. Umpierrez et al
40
 showed a prevalence of thyroid dysfunction to 
be 33%. All patients had hypothyroidism mostly subclinical. None had 
hyperthyroidism. 80% of them were positive for TPOA antibodies. Among the 
TPOA positive individuals, 83% of females and 51% of males developed 
hypothyroidism on follow up. In their study, TPOA positivity as a predictor for 
development of thyroid dysfunction was assessed and they found out 67% 
positive predictive value and a 90% negative predictive value. As per their 
study, patients who were TPO positive were 17.91 times as likely to develop 
hypothyroidism as patients who were TPO negative (95% CI 3.89–82.54). 
Miguel Fernandez-castaner
43
 investigated 111 adult T1D patients and found 
15.3% thyroid dysfunction, and all of them were positive for thyroid antibodies.  
None of the TPOA negative individuals developed thyroid function 
abnormality.  
 Similarly in the report by Maugendre D et al
33
, 24% had abnormal thyroid 
function among anti-TPO positive patients, while none among those who were 
negative for the antibody. Gemma C et al is in favour with this. 
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 Similar to the report by Guillermo E. Umpierrez et al
39
, all our patients 
with thyroid dysfunction had only hypothyroidism. Most of them were 
subclinical. While we didn‟t find any hyperthyroid patients, hyperthyroidism 
has been reported as a presentation of thyroid autoimmunity in T1D in several 
studies.  
 In the study by Gemma C et al
34
, 72% of patients with thyroid 
autoimmunity developed thyroid dysfunction. 68% hypothyroidism, 4% 
hyperthyroidism. Roldán MB et al
30 
found 11% subclinical hypothyroidism, 3% 
overt hypothyroidism, 3% subclinical hyperthyroidism and 6% overt 
hyperthyroidism among those who were positive for AITD.  
 Adriana Franzese et al
38
 investigated 37 DM1 patients with TPO-AB, the 
prevalence of hypothyroidism was 16% and that of hyperthyroidism was 4% 
among them. On the whole, in agreement with many similar reports, we 
observed a higher prevalence of thyroid dysfunction mostly as subclinical 
hypothyroidism in type 1 diabetes than in the general population, especiallyin 
patients with positive TPO antibodies. 
THYROID AUTOIMMUNITY IN RELATION TO GENDER 
 Generally thyroid autoimmunity is more common in females than in 
males, this holds good for T1DM also as per many cross-sectional as well as 
prospective studies. In our study also, there is preponderance for female to 
develop thyroid autoimmunity. 
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 Gemma C et al
34
 reported female preponderance. 18.3% females had 
AITD whereas it was 7% in males. Olga Kordonouriet al
35
 showed a similar 
female preponderance and they had 63% of AITD patients as females. Reports 
by Holl RW et al
46
, O Kordonouri et al
35
, Adriana Franzese et al
38
, Jennifer M. 
Barker et al
37
support this gender difference. 
 Miguel Fernandez-castaner et al
43 
investigated 814 T1D patients and 
found a female predominance among TPOA positive patients but not among    
Tg -Ab positive patients. 
 Guillermo E. Umpierrez et al
44
found a higher incidence of 
hypothyroidism in TPO positive females than in antibody positive males, but 
reported the prevalence of thyroid autoimmunity as equal in both the sex. 
 Menon PS et al
40
 showed that sex doesn‟t influence the development of 
thyroid autoimmunity among Indian paediatric population. 
 Sarah J. Glastras et al
41
, D Hansen, FN Bennedbaek et al
47
, D Hansen 
Penny R et al
48
 Aaron Hanukoglu et al
36
 , Maugendre D et al
33
 are in agreement 
with equal prevalence in both the sex. 
 As in general population, thyroid autoimmunity is expected to be more 
common in female.  
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THYROID AUTOIMMUNITY IN RELATION TO AGE 
 Many studies have shown that the prevalence of thyroid autoimmunity is 
high among older patients than younger patients. In our study we find a 
significant association between increasing age group and thyroid antibodies 
Olga Kordonouri et al states that the prevalence of significant thyroid antibody 
titers increases with increasing age of patients and reached its maximum in the 
15- to 20year age group. Holl RW et al
46
 found the prevalence of AITD to 
increase dramatically with age. O Kordonouri R, Hartmann et al
35
 reports the 
prevalence to be high in > 12 years age group. 
 Jennifer M. Barker et al
37
, Czerniawska E et al
49
 agree the higher 
prevalence in older age. In the study by Gemma C et al, there is a significant 
age difference between those who develop thyroid dysfunction and those who 
remain euthyroid among the TPOA positive subjects. Thyroid function 
abnormality being more common among those who were older at the onset of 
diabetes. But age of onset does not influence the positivity for the antibodies. 
Guillermo E. Umpierrez et al
39
, Sarah J. Glastras et al
41
, D Hansen et al
47
,  
Maugendre D et al
33
 observed no significant age difference. Gregory Goodwin 
et al
50
 is totally against other reports by stating that the risk of thyroid 
autoimmunity is more in sibling pairs with younger age of onset of diabetes. 
 The influence of age of onset of diabetes or age of the patient on 
development of AITD may or may not be there depending on the population. 
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THYROID AUTOIMMUNITY IN RELATION TO DURATION OF 
DIABETES 
 According to many prospective studies incidence of thyroid 
autoimmunity increases as years pass by since the diagnosis of diabetes. The net 
result would be a higher prevalence of AITD among patients with longer 
duration of diabetes than the newly diagnosed cases. In our study there is 
significant association between duration of diabetes and development of TPOA 
positive  persons.  
 According to Olga Kordonouri et al prevalence increases with increasing 
duration. O Kordonouri, R Hartmann et al and Jennifer M. Barker et al favour 
the same. Adriana Franzese et al found a higher prevalence in those with longer 
duration particularly when they are in peripubertal age group. 
 D Hansen et al, Maugendre D et al showed that the duration of diabetes 
doesn‟t influence development of AITD. The Indian study by Menon PS et al 
also observed that the thyroid autoimmunity did not change with duration. 
In the report by Guillermo E. Umpierrez et al most subjects with positive TPO 
antibodies (17 of 18) tested positive at the beginning of the study and remained 
positive throughout the study period. Only one patient with an initial negative 
TPO titer developed low-TPO titer after 12 years of follow-up. 
 In the prospective study by Gemma C et al, TPOA was measured only at 
the onset of diabetes. Future conversion to positivity was not assessed. But only 
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one of the initial TPOA negative individuals developed hypothyroidism who 
later turned out to be positive for antibody. 
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CONCLUSION 
 There is higher prevalence of thyroid autoimmunity in type 1 diabetes 
mellitus 
 Most of the patients develop subclinical form of disease  
 Gender, age, and duration of diabetes have a significant association with 
autoimmune thyroid disease                                
 Hypothyroidism is much more common than hyperthyroidism in 
autoimmune thyroid disease associated with type 1 diabetes 
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SUMMARY 
 Our study confirms the association between T1DM and autoimmune 
thyroid disease and suggests all Type 1 Diabetes Mellitus individuals should be 
screened for autoimmune thyroid disease at the time of diagnosis soon after 
metabolic control of glucose and to be followed up with annual TSH 
measurement in case of autoimmune positive individuals.  
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                                    PROFORMA 
 
 
 NAME                                        : 
 SEX                                           : 
 AGE                                           : 
 AGE OF ONSET OF DISEASE : 
 DURATION OF DIABETES       : 
 SYMPTOMS / SIGNS 
OF HYPOTHYROIDISM            : 
 SYMPTOMS / SIGNS 
OF HYPERTHYROIDISM          : 
 CO EXISTING MEDICAL 
ILLNESS                                    : 
 THYROID PROFILE 
 TOTAL T3                                  : 
 TOTAL T4                                  : 
 TSH                                            : 
 TPO ANTIBODY                        : 
s.no SEX AGE AGE OF ONSET DURATION   T3   T4    TSH TPO THYROID  STATUS
1 M 23 11 12 86 6.8 1.4 N EUTHYROID
2 M 32 15 17 98 7.4 8.9 P SUBHYPOTHYROID
3 F 21 8 13 91 11.2 0.7 N EUTHYROID
4 M 23 18 13 89 6.9 1.4 N EUTHYROID
5 M 27 21 6 104 8.4 1.9 N EUTHYROID
6 M 21 15 6 126 8.9 1.6 N EUTHYROID
7 F 32 22 10 79 7.5 2.3 N EUTHYROID
8 F 34 17 17 24 3.1 18 P HYPOTHYROID
9 M 28 21 7 92 5.8 3.1 N EUTHYROID
10 F 31 17 14 78 6.4 1.6 N EUTHYROID
11 F 24 14 10 82 8.8 2.8 N EUTHYROID
12 M 30 17 13 94 6.9 3.4 N EUTHYROID
13 F 22 9 13 109 9.4 2.5 N EUTHYROID
14 F 25 7 18 46 2.3 12 P HYPOTHYROID
15 F 16 6 10 134 7.4 2.3 N EUTHYROID
16 M 21 10 11 143 6.3 0.6 N EUTHYROID
17 M 15 9 6 86 8.6 1.7 N EUTHYROID
18 F 27 12 15 80 6.5 9.2 P SUBHYPOTHYROID
19 M 19 11 8 95 10.7 2.4 N EUTHYROID
20 M 29 15 14 88 9.5 3 N EUTHYROID
21 M 21 13 8 125 6.7 3.5 N EUTHYROID
22 F 27 12 15 128 5.8 2.7 P EUTHYROID
23 M 31 17 14 112 6.1 1.8 N EUTHYROID
24 F 21 15 6 92 11.4 2.8 N EUTHYROID
25 F 35 21 14 86 9.4 8 P SUBHYPOTHYROID
26 M 31 21 10 82 6.4 2.3 N EUTHYROID
27 F 31 11 20 77 9.3 1.6 N EUTHYROID
28 M 27 16 11 104 10.1 2.8 N EUTHYROID
29 M 24 13 11 93 8.2 7.4 P SUBHYPOTHYROID
30 F 29 15 14 89 6.4 2.7 N EUTHYROID
31 F 25 10 15 132 8.4 3.1 N EUTHYROID
32 F 19 12 7 118 9.6 1.9 N EUTHYROID
33 M 16 8 8 112 10.4 3.2 N EUTHYROID
34 F 19 7 12 79 5.9 1.8 N EUTHYROID
35 M 26 5 21 86 8.2 8 P SUBHYPOTHYROID
36 F 14 5 9 112 6.8 4.2 N EUTHYROID
37 F 27 12 15 96 9.4 3.1 N EUTHYROID
38 M 17 14 3 128 7.9 2.4 N EUTHYROID
39 M 18 11 7 134 9.8 1.6 N EUTHYROID
40 M 22 7 15 108 10.6 2.7 N EUTHYROID
41 F 15 4 11 89 5.5 4.1 N EUTHYROID
42 M 16 5 11 84 5.9 2.6 N EUTHYROID
43 F 18 6 12 112 6.4 2.2 N EUTHYROID
44 F 32 16 16 135 5.6 7.8 P SUBHYPOTHYROID
45 M 26 21 5 107 6.7 2.5 N EUTHYROID
46 M 32 21 11 97 7.5 3.6 N EUTHYROID
47 F 31 14 17 78 5.5 1.6 P TPO EUTHYROID
48 F 26 11 15 69 5.9 8.4 N EUTHYROID
49 F 16 5 11 79 6.2 2.4 N EUTHYROID
50 M 21 12 9 90 5.8 3.5 N EUTHYROID
MASTER  CHART
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s.no SEX AGE AGE OF ONSET DURATION   T3   T4    TSH TPO THYROID  STATUS
51 M 17 11 6 102 7.1 2.7 N EUTHYROID
52 M 17 9 8 116 5.7 4.1 N EUTHYROID
53 F 19 7 12 93 5.6 8.4 P SUBHYPOTHYROID
54 F 23 11 12 79 5.9 3.5 N EUTHYROID
55 M 16 12 4 88 7.3 4.2 N EUTHYROID
56 M 21 15 14 97 5.7 2.7 N EUTHYROID
57 M 17 14 3 115 6.7 3.5 N EUTHYROID
58 F 14 12 2 152 7.3 4.2 N EUTHYROID
59 F 16 13 3 95 6.8 3.1 N EUTHYROID
60 M 18 15 3 80 5.7 1.6 N EUTHYROID
61 F 17 13 4 31 2.1 23 P HYPOTHYROID
62 M 19 14 5 110 5.9 1.6 N EUTHYROID
63 M 23 17 6 118 6.4 2.2 N EUTHYROID
64 M 21 18 3 96 8.1 3.6 N EUTHYROID
65 F 15 9 6 79 6.2 4.1 N EUTHYROID
66 F 19 11 8 89 5.7 2.7 N EUTHYROID
67 F 20 14 6 84 6.7 4.2 N EUTHYROID
68 F 21 9 12 123 5.9 6.8 P SUBHYPOTHYROID
69 M 22 8 14 115 6.2 3.1 N EUTHYROID
70 F 24 15 9 97 5.8 1.7 P TPO EUTHYROID
71 M 17 7 10 78 6.7 2.4 N EUTHYROID
72 F 15 8 7 94 5.8 1.8 N EUTHYROID
73 F 15 5 10 150 7.4 9.5 P TPO EUTHYROID
74 M 14 11 3 132 7.1 3.8 N EUTHYROID
75 M 17 13 4 105 6.2 4.2 N EUTHYROID
76 M 14 11 3 91 5.5 1.7 N EUTHYROID
77 M 18 15 3 82 6.2 1.9 N EUTHYROID
78 M 15 13 2 94 8.1 2 N EUTHYROID
79 F 17 11 6 87 7.4 1.4 N EUTHYROID
80 F 19 14 5 112 6.3 0.7 N EUTHYROID
81 M 16 14 2 135 5.9 1.5 N EUTHYROID
82 M 19 12 7 127 6.3 0.8 N EUTHYROID
83 M 21 16 5 109 8.2 2.1 N EUTHYROID
84 F 26 19 7 93 5.6 7.4 P SUBHYPOTHYROID
85 F 15 11 4 91 5.9 3.1 N EUTHYROID
86 M 19 14 5 84 6.4 2.5 N EUTHYROID
87 M 25 17 8 127 5.7 1.2 N EUTHYROID
88 M 26 15 11 104 7.8 0.7 N EUTHYROID
89 M 21 17 4 97 6.9 4.1 N EUTHYROID
90 F 17 12 5 81 6.1 3.6 N EUTHYROID
91 F 15 8 7 78 5.7 7.9 P SUBHYPOTHYROID
92 M 19 12 7 84 6.2 4 N EUTHYROID
93 M 22 16 6 132 6.7 1.4 N EUTHYROID
94 F 21 14 7 127 7.4 2.4 N EUTHYROID
95 F 17 12 5 108 7.8 0.7 N EUTHYROID
96 M 19 14 5 79 5.7 4.1 N EUTHYROID
97 M 25 18 7 89 6.4 1.5 N EUTHYROID
98 M 27 13 14 92 7.2 3.2 N EUTHYROID
99 M 30 15 15 96 6 7.6 P TPO EUTHYROID
100 F 23 17 6 124 6.6 2.2 N EUTHYROID
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                                    KEY TO MASTER CHART 
M    –  Male 
F    – Female 
T3    –  Triiodothyronine 
T4    –  Tetraiodothyronine 
Subhypothyroid –  Subclinical hypothyroidism 
TPOA euthyroid –  TPOA positive euthyroidism 
P     –  Positive 
N     –  Negative 
